• John Edward Connolly

    Senior Principal Investigator and Director for Translational Immunology/Institute of Molecular and Cellular Biology (IMCB)

  • Dr. Connolly is the CSO of Tessa Therapeutics, a Senior Principal Investigator and Director for Translational Immunology at the Institute of Molecular and Cellular Biology (IMCB). As a human immunologist, his research interests focus on target discovery for immune modulation. An Adjunct Associate Professor of Immunology at Baylor University, he served on the Board of Governors for the Institute of Biomedical Sciences.

    Dr. Connolly received his Ph.D. in Immunology from Dartmouth Medical School and studied human dendritic cell biology under Dr. Michael Fanger. During this time, he was involved in the development of immunotherapeutic preclinical models and clinical trials for Glioblastoma multiforme (GBM). He moved to the Baylor Institute for Immunology Research, a fully translational research institute dedicated to rationally designed vaccines against cancer and infectious disease. Dr. Connolly served as the Director of Research Initiatives for the Baylor Research Institute, leading a large integrated translational research resource and multi-institutional programs. During his tenure at Baylor, Dr. Connolly was a central core facility director of the NIAID Centers for Translational Research on Human Immunology and Biodefense, an NIH funded consortium of basic, translational research and clinical trials focused on vaccine design. Dr. Connolly is the past President of the Board of Directors of The American Cancer Society in N. Texas.